Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Alzheimer's Disease

  Free Subscription

Articles published in J Neurol Neurosurg Psychiatry

Retrieve available abstracts of 30 articles:
HTML format

Single Articles

    November 2022
  1. AYTON S, Janelidze S, Kalinowski P, Palmqvist S, et al
    CSF ferritin in the clinicopathological progression of Alzheimer's disease and associations with APOE and inflammation biomarkers.
    J Neurol Neurosurg Psychiatry. 2022 Nov 10. pii: jnnp-2022-330052.
    PubMed     Abstract available

    August 2022
  2. HALBGEBAUER S, Steinacker P, Hengge S, Oeckl P, et al
    CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2022 Aug 22. pii: jnnp-2021-328646.
    PubMed     Abstract available

  3. O'CONNOR A, Abel E, Benedet AL, Poole T, et al
    Plasma GFAP in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study.
    J Neurol Neurosurg Psychiatry. 2022 Aug 10. pii: jnnp-2022-329663.

  4. BARBA L, Abu Rumeileh S, Bellomo G, Paolini Paoletti F, et al
    Cerebrospinal fluid beta-synuclein as a synaptic biomarker for preclinical Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2022 Aug 9. pii: jnnp-2022-329124.
    PubMed     Abstract available

    July 2022
  5. DAVID MCB, Del Giovane M, Liu KY, Gostick B, et al
    Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer's disease: systematic review and meta-analysis.
    J Neurol Neurosurg Psychiatry. 2022 Jul 5. pii: jnnp-2022-329136.
    PubMed     Abstract available

    June 2022
  6. OVERMAN MJ, Drummond N, Butler CR, Ahmed S, et al
    Tracking the clinical progression of posterior cortical atrophy: implications for post-diagnostic and therapeutic interventions.
    J Neurol Neurosurg Psychiatry. 2022;93:683-684.

  7. PARNETTI L, Paolini Paoletti F, Gaetani L
    Blood biomarkers may distinguish among dementia disorders.
    J Neurol Neurosurg Psychiatry. 2022;93:571.

    April 2022
  8. OECKL P, Anderl-Straub S, Von Arnim CAF, Baldeiras I, et al
    Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion.
    J Neurol Neurosurg Psychiatry. 2022 Apr 27. pii: jnnp-2021-328547.
    PubMed     Abstract available

    March 2022
  9. CHENG L, Li W, Chen Y, Lin Y, et al
    Plasma Abeta as a biomarker for predicting Abeta-PET status in Alzheimer's diseasea systematic review with meta-analysis.
    J Neurol Neurosurg Psychiatry. 2022 Mar 3. pii: jnnp-2021-327864.
    PubMed     Abstract available

  10. KONCZ R, Thalamuthu A, Wen W, Catts VS, et al
    The heritability of amyloid burden in older adults: the Older Australian Twins Study.
    J Neurol Neurosurg Psychiatry. 2022;93:303-308.
    PubMed     Abstract available

    February 2022
  11. LAGARDE J, Olivieri P, Tonietto M, Tissot C, et al
    Tau-PET imaging predicts cognitive decline and brain atrophy progression in early Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2022 Feb 28. pii: jnnp-2021-328623.
    PubMed     Abstract available

    January 2022
  12. CHOULIARAS L, Thomas A, Malpetti M, Donaghy P, et al
    Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.
    J Neurol Neurosurg Psychiatry. 2022 Jan 25. pii: jnnp-2021-327788.
    PubMed     Abstract available

  13. HALBGEBAUER S, Steinacker P, Verde F, Weishaupt J, et al
    Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS.
    J Neurol Neurosurg Psychiatry. 2022;93:68-74.
    PubMed     Abstract available

    November 2021
  14. ZHOU D, Li A, Li X, Zhuang W, et al
    Effects of 40 Hz transcranial alternating current stimulation (tACS) on cognitive functions of patients with Alzheimer's disease: a randomised, double-blind, sham-controlled clinical trial.
    J Neurol Neurosurg Psychiatry. 2021 Nov 11. pii: jnnp-2021-326885.

  15. ALCOLEA D, Delaby C, Munoz L, Torres S, et al
    Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias.
    J Neurol Neurosurg Psychiatry. 2021;92:1206-1214.
    PubMed     Abstract available

    September 2021
  16. CHONG JR, Ashton NJ, Karikari TK, Tanaka T, et al
    Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances.
    J Neurol Neurosurg Psychiatry. 2021 Sep 11. pii: jnnp-2021-327370.
    PubMed     Abstract available

    June 2021
  17. RAUCHMANN BS, Schneider-Axmann T, Perneczky R
    Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Abeta-PET and cognition.
    J Neurol Neurosurg Psychiatry. 2021 Jun 29. pii: jnnp-2020-325537.
    PubMed     Abstract available

  18. CHEUNG CY, Mok V, Foster PJ, Trucco E, et al
    Retinal imaging in Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2021 Jun 9. pii: jnnp-2020-325347.
    PubMed     Abstract available

    April 2021
  19. SINGLETON E, Hansson O, Pijnenburg YAL, La Joie R, et al
    Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2021 Apr 13. pii: jnnp-2020-325497.
    PubMed     Abstract available

    February 2021
  20. OLIVEIRA FPM, Walker Z, Walker RWH, Attems J, et al
    (123)I-FP-CIT SPECT in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease: a new quantitative analysis of autopsy confirmed cases.
    J Neurol Neurosurg Psychiatry. 2021 Feb 4. pii: jnnp-2020-324606.
    PubMed     Abstract available

    December 2020
  21. HALBGEBAUER S, Oeckl P, Steinacker P, Yilmazer-Hanke D, et al
    Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2020 Dec 30. pii: jnnp-2020-324306.
    PubMed     Abstract available

    When hearing loss masquerades as cognitive decline.
    J Neurol Neurosurg Psychiatry. 2020;91:1248.

    November 2020
  23. KEIR LHM, Breen DP
    REM sleep behaviour disorder in patients without synucleinopathy.
    J Neurol Neurosurg Psychiatry. 2020;91:1239-1240.

    October 2020
  24. CHU CS, Li CT, Brunoni AR, Yang FC, et al
    Cognitive effects and acceptability of non-invasive brain stimulation on Alzheimer's disease and mild cognitive impairment: a component network meta-analysis.
    J Neurol Neurosurg Psychiatry. 2020 Oct 28. pii: jnnp-2020-323870.
    PubMed     Abstract available

  25. LU L, Zheng X, Wang S, Tang C, et al
    Anti-Abeta agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis.
    J Neurol Neurosurg Psychiatry. 2020 Oct 12. pii: jnnp-2020-323497.
    PubMed     Abstract available

  26. KOH W, Lim L, Low A, Wong B, et al
    Development and validation of a brief visual based cognitive screening tool for dementia: the Visual Cognitive Assessment Test short-form (VCAT-S).
    J Neurol Neurosurg Psychiatry. 2020;91:1122-1123.

    September 2020
  27. AGIN A, Blanc F, Bousiges O, Villette C, et al
    Environmental exposure to phthalates and dementia with Lewy bodies: contribution of metabolomics.
    J Neurol Neurosurg Psychiatry. 2020;91:968-974.
    PubMed     Abstract available

  28. BENUSSI A, Karikari TK, Ashton N, Gazzina S, et al
    Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration.
    J Neurol Neurosurg Psychiatry. 2020;91:960-967.
    PubMed     Abstract available

    May 2020
  29. CHEN S, Honda T, Ohara T, Hata J, et al
    Serum homocysteine and risk of dementia in Japan.
    J Neurol Neurosurg Psychiatry. 2020;91:540-546.
    PubMed     Abstract available

  30. SENOVA S, Fomenko A, Gondard E, Lozano AM, et al
    Anatomy and function of the fornix in the context of its potential as a therapeutic target.
    J Neurol Neurosurg Psychiatry. 2020;91:547-559.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.